ACM
FOLD

Antonetti Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Antonetti Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-900
Closed -$10K – 344
2022
Q2 		$10K Hold
900
– – 0.01% 224
2022
Q1 		$9K Hold
900
– – 0.01% 261
2021
Q4 		$10K Hold
900
– – 0.01% 304
2021
Q3 		$9K Buy
+900
New +$9.21K 0.01% 321

Other funds holding FOLD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Antonetti Capital Management's FOLD Position: Q3 2022 in Review

Antonetti Capital Management sold out of Amicus Therapeutics (FOLD) in Q3 2022, closing a stake of 900 shares — an estimated $10K sold.

Antonetti Capital Management first reported a position in FOLD in Q3 2021 and held it in 4 quarters. The position peaked at $10K in Q2 2022. 222 funds tracked by Wall St. Rank hold FOLD as of Q3 2022.

  • Antonetti Capital Management reported no remaining Amicus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Antonetti Capital Management sold 900 Amicus Therapeutics shares in Q3 2022, an estimated $10K.
  • Antonetti Capital Management first reported a position in Amicus Therapeutics in Q3 2021 and held it in 4 quarters.
  • Antonetti Capital Management's Amicus Therapeutics position peaked at $10K in Q2 2022.
  • 222 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2022.

Based on Antonetti Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.